Slingshot members are tracking this corporate initiative:
Ipsen (IPSEY) Completes Acquisition of Clementia Pharmaceuticals (CMTA)
Do you think this event is important to the companies below? How will it affect their stock price?
Ipsen’s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Apr 18, 2019 Projected Implementation: Q2, 2019 Relevance Tracked Until: Q3, 2019
Don’t see a project related to the strategic initiative you care about?
Related Keywords Acquisiton, Palovarotene